SaniCart Mobile, Micro-Fogging Sanitation System, When Paired with an EPA-Approved COVID-19 Disinfectant, Can Kill Coronaviruses in the Air and on surfaces

The fog produced by SaniCart engulfs enclosed areas with a cloud of disinfectant that remains suspended in the air and covers all surfaces for complete disinfection.

SaniCart patented nozzle creates a micro-fog to achieve this breakthrough air and surface disinfectant coverage in the fight against COVID-19.

“The EPA has released List N: Disinfectants for Use Against SARS-CoV-2. SaniCart is the missing puzzle piece as it simplifies and automates the process of effectively applying these sanitizing agents. Since SaniCart can operate with a wide range of disinfectants, we have ramped up manufacturing to provide this vehicle to the frontlines, including hospitals, ambulances, grocery stores and government agencies, to keep their facilities sanitized and protect their workers while they continue to serve us during this immediate time of crisis,” said Nadya Merchant, M.P.H., PhD., Scientific Director at Aguair LLC.

Last week Aguair partnered with TwinOxide Inc., whose chlorine dioxide (EPA Reg. No. 86054-1) is safe and effective against many resistive strains of pathogens and viruses, including coronaviruses.

“When SaniCart was used to dispense TwinOxide, we were able to quickly achieve and maintain the EPA-prescribed concentration of chlorine dioxide throughout the test environment, thereby killing any coronaviruses that might be present in the air and on surfaces,” said Dr. Joe Nieusma of TwinOxide.

Recent studies have shown that COVID-19 remains suspended as droplets in air for up to three hours, after which it settles onto surfaces and can survive for multiple days. SaniCart addresses this lifecycle of COVID-19 by thoroughly fogging the air and covering surfaces, including nooks and crannies, to completely disinfect any enclosed area. SaniCart provides the user with an efficient automated process that can be implemented by just rolling the cart into a room and pressing the start button to deliver any disinfectant of choice.

Aguair and its parent company, Prodew Inc., are utilizing SaniCart and their ClensAir air purifier to disinfect and maintain sanitation in their own facilities. In this way, they are providing their workers with a more sanitized environment so that they can continue to manufacture and meet the increased demand for this vital equipment from their customers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version